Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Understanding the risks that lead to complications after bladder cancer surgery
November 11, 2014
Drs.
Rodney Breau
and Luke Lavallée have published a new study in
PLOS ONE
regarding complications following the removal of the bladder to treat bladder cancer (radical cystectomy). The study found that 55% of patients experienced a post-operative complication following such a surgery, the most common of which was the need for a blood transfusion (38% of patients). It also identified risk factors for experiencing a post-operative complication, which included older age, female gender, pre-operative health status, chronic obstructive pulmonary disease, low serum albumin, radiotherapy, recent transfusion, and length of operation. Radical cystectomy is often the best treatment option for patients with bladder cancer, but the high risk for complications associated with this procedure warrants more studies to improve patient safety. Dr. Breau and his colleagues have previously identified that lysine inhibitors (to prevent bleeding during surgery) are underutilized for patients receiving radical cystectomy. They are currently leading a multicentre CIHR-funded randomized trial (TACT trial) assessing whether the use of lysine inhibitors is safe and might reduce the need for blood transfusion.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. OHRI includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.
Media contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
613-737-8899 x73687
613-323-5680 (cell)